[HTML][HTML] Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced …
C Zhou, YL Wu, G Chen, J Feng, XQ Liu, C Wang… - Annals of …, 2015 - Elsevier
Background The OPTIMAL study was the first study to compare efficacy and tolerability of the
epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) erlotinib, versus …
epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) erlotinib, versus …
Randomized phase II trial of erlotinib beyond progression in advanced erlotinib-responsive non-small cell lung cancer
Background. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy
is clearly beneficial in patients with advanced EGFR-mutated non-small cell lung cancer …
is clearly beneficial in patients with advanced EGFR-mutated non-small cell lung cancer …
[HTML][HTML] A randomized phase II trial of erlotinib or erlotinib and bevacizumab in patients with advanced EGFR mutant non-small cell lung cancer (NSCLC)
TE Stinchcombe, PA Janne, X Wang… - Annals of …, 2018 - annalsofoncology.org
Background: A retrospective subset analysis from a phase 3 trial, and preclinical data
supported prospective study of elrotinib and bevacizumab in patients (pts) with EGFR mutant …
supported prospective study of elrotinib and bevacizumab in patients (pts) with EGFR mutant …
[HTML][HTML] A prospective, multicentre phase II trial of low-dose erlotinib in non-small cell lung cancer patients with EGFR mutations pretreated with chemotherapy …
K Yamada, H Aono, Y Hosomi, H Okamoto… - European Journal of …, 2015 - Elsevier
Background Low-dose erlotinib may be as effective as gefitinib or erlotinib at full dose in non-
small cell lung cancer (NSCLC) patients with activating mutations of the epidermal growth …
small cell lung cancer (NSCLC) patients with activating mutations of the epidermal growth …
Clinical outcomes of gefitinib and erlotinib in patients with NSCLC harboring uncommon EGFR mutations: A pooled analysis of 438 patients
C Wang, K Zhao, S Hu, W Dong, Y Gong, M Li, C Xie - Lung Cancer, 2022 - Elsevier
Background The purpose of this study was to investigate the outcomes of gefitinib and
erlotinib in patients with non-small cell lung cancer (NSCLC) with uncommon epidermal …
erlotinib in patients with non-small cell lung cancer (NSCLC) with uncommon epidermal …
NEJ026: phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations
M Maemondo, T Fukuhara, S Sugawara… - Annals of …, 2016 - annalsofoncology.org
Background Development of treatment for EGFR-mutated non-small-cell lung cancer
(NSCLC) had been focused on monotherapy of gefitinib, erlotinib, or afatinib. However …
(NSCLC) had been focused on monotherapy of gefitinib, erlotinib, or afatinib. However …
Combined analysis of two Phase II studies evaluating first-line erlotinib in NSCLC with EGFR mutation: JO22903/JO25567
S Atagi, K Goto, T Seto, N Yamamoto… - Annals of …, 2015 - annalsofoncology.org
Background: First-line erlotinib monotherapy showed good efficacy and safety in two phase
II studies; JO22903 (K Goto et al. Lung Cancer 2013) and JO25567 (T Seto et al. Lancet …
II studies; JO22903 (K Goto et al. Lung Cancer 2013) and JO25567 (T Seto et al. Lancet …
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a …
C Zhou, YL Wu, G Chen, J Feng, XQ Liu… - The lancet …, 2011 - thelancet.com
Background Activating mutations in EGFR are important markers of response to tyrosine
kinase inhibitor (TKI) therapy in non-small-cell lung cancer (NSCLC). The OPTIMAL study …
kinase inhibitor (TKI) therapy in non-small-cell lung cancer (NSCLC). The OPTIMAL study …
[HTML][HTML] First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III …
Background The phase III, randomized, open-label ENSURE study (NCT01342965)
evaluated first-line erlotinib versus gemcitabine/cisplatin (GP) in patients from China …
evaluated first-line erlotinib versus gemcitabine/cisplatin (GP) in patients from China …
[HTML][HTML] A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations
JJ Yang, Q Zhou, HH Yan, XC Zhang, HJ Chen… - British journal of …, 2017 - nature.com
Background: A phase III trial was conducted to compare the safety and efficacy of erlotinib
with that of gefitinib in advanced non-small cell lung cancer harbouring epidermal growth …
with that of gefitinib in advanced non-small cell lung cancer harbouring epidermal growth …